Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcytes 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the…
Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics
From 100 to 600 patients: to support patients suffering from acne, Avène,…
Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa net sales recorded by Orion has potential to exceed EUR 1 billion in the future
January 14, 2026 01:30 ET | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE…
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Not intended for US and UK audiences BI 765423 has been developed…
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders…
Cango Receives Buy Rating, Upbeat on its Asset-light Mining Model and AI Potential
DALLAS, Texas, Dec. 24, 2025 /PRNewswire/ -- Greenridge Capital has initiated coverage on…
FITUR 2026 to be a showcase for India’s great tourism potential and business opportunities with Europe
India strengthens its presence at FITUR at a key moment in the…
Society Pass Incorporated (Nasdaq: SOPA) Rolls Out M&A Strategy to Capture Potential Significant Valuation Opportunities in Global Landscape of Privately Held Companies
December 15, 2025 10:55 ET | Source: Society Pass Incorporated NEW YORK,…
Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed…
ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L…
